ArticleThe primary care companion for CNS disorders2011
Treatment of generalized anxiety disorder: a comprehensive review of the literature for psychopharmacologic alternatives to newer antidepressants and benzodiazepines.
Article in The primary care companion for CNS disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 41 citations in OpenAlex.
- Aligning the many definitions of treatment resistance in anxiety disorders: A systematic review.Depression and anxiety · 2019Pooled it
- A double-blind, randomized, placebo-controlled, fixed-dose phase III study of vilazodone in patients with generalized anxiety disorder.Depression and anxiety · 2015Trial
- Modulating Anxiety-Like Behaviors in Neuropathic Pain: Role of Anterior Cingulate Cortex Astrocytes Activation.CNS neuroscience & therapeutics · 2025Article
- Perineuronal Nets in Syrian Hamsters: Anatomical Localization, Sex Differences, Diurnal Variation, and Response to Social Stress.Brain and behavior · 2024Article
- Anxiolytic and sedative effects of sodium valproate with different experimental paradigms in male and female rats.Neuropsychopharmacology reports · 2024Article
- Promnesic, Anxiolytic and Antioxidant Effects ofPlants (Basel, Switzerland) · 2023Article
- Generalised Anxiety Disorder and Depression: Contemporary Treatment Approaches.Advances in therapy · 2021Article
- Anxiolytic, Promnesic, Anti-Acetylcholinesterase and Antioxidant Effects of Cotinine and 6-Hydroxy-L-Nicotine in Scopolamine-Induced Zebrafish (Antioxidants (Basel, Switzerland) · 2021Article
- Brain-derived neurotrophic factor signaling mitigates the impact of acute social stress.Neuropharmacology · 2019Article
- Psychogenic Polydipsia - Management Challenges.Shanghai archives of psychiatry · 2017Article
- Of mice and marbles: Novel perspectives on burying behavior as a screening test for psychiatric illness.Cognitive, affective & behavioral neuroscience · 2016Article
- Herbal medicine use in adults who experience anxiety: A qualitative exploration.International journal of qualitative studies on health and well-being · 2015Article
- Article
- The involvement of magnoflorine in the sedative and anxiolytic effects of Sinomeni Caulis et Rhizoma in mice.Journal of natural medicines · 2013Article
- Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs.BMC genomics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveGeneralized anxiety disorder (GAD) is common, chronic, and debilitating. Treatment with benzodiazepines and newer antidepressants is often inadequate. This article reviews the effectiveness of alternative and augmenting medications, such as older antidepressants, antipsychotics, anticonvulsants, and β-blockers. DATA SOURCES: A search using MEDLINE (1980 to week 4 of May 2010) with the key words generalized anxiety disorder or GAD and therapeutics or treatment was conducted. Articles included adult patients with a GAD diagnosis that established chronicity of illness. These included a small number of studies that used DSM-III criteria but added a chronicity of symptoms and included all studies that used DSM-III-R and DSM-IV criteria. Articles that did not include medications or that exclusively focused on newer antidepressants (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, bupropion, and mirtazapine), buspirone, benzodiazepines, or herbal or investigational medications were excluded. Review articles and non-English-language articles were also excluded.
resultsThirty-six studies were reviewed. All of the references were then analyzed, and key portions were extracted. Many studies were open trials. Double-blind, placebo-controlled studies with imipramine, risperidone, olanzapine, hydroxyzine, ondansetron, tiagabine, valproate, and pregabalin had been conducted. Imipramine, hydroxyzine, valproate, and pregabalin were the most effective, although risperidone, olanzapine, ziprasidone, and aripiprazole may also reduce symptoms.
conclusionsSeveral medication strategies can be considered as promising alternatives or augmenting to antidepressant or benzodiazepine therapy in GAD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.